Q4 EPS Forecast for Merit Medical Systems Reduced by Analyst

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Equities research analysts at Zacks Research reduced their Q4 2024 earnings per share estimates for Merit Medical Systems in a research report issued on Wednesday, November 20th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings per share of $0.81 for the quarter, down from their prior estimate of $0.83. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q3 2026 earnings at $1.07 EPS.

Merit Medical Systems (NASDAQ:MMSI) last announced its earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.80 by $0.06. The firm had revenue of $339.85 million during the quarter, compared to analyst estimates of $334.60 million. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.75 EPS.

MMSI has been the subject of several other research reports. StockNews.com lowered shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a research note on Sunday, November 3rd. Needham & Company LLC reissued a “buy” rating and issued a $109.00 target price on shares of Merit Medical Systems in a research report on Thursday, October 31st. Barrington Research reaffirmed an “outperform” rating and set a $114.00 price target on shares of Merit Medical Systems in a research report on Thursday, October 31st. Piper Sandler reissued an “overweight” rating and issued a $110.00 price objective (up previously from $100.00) on shares of Merit Medical Systems in a report on Monday, September 9th. Finally, Wells Fargo & Company upped their price objective on shares of Merit Medical Systems from $85.00 to $103.00 and gave the company an “equal weight” rating in a report on Monday, September 16th. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $103.36.

Merit Medical Systems Stock Performance

Shares of MMSI stock opened at $104.92 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. The firm has a market cap of $6.11 billion, a price-to-earnings ratio of 51.43, a P/E/G ratio of 2.62 and a beta of 0.89. Merit Medical Systems has a 52 week low of $65.46 and a 52 week high of $106.87. The firm’s 50-day simple moving average is $98.70 and its two-hundred day simple moving average is $91.16.

Institutional Trading of Merit Medical Systems

Large investors have recently added to or reduced their stakes in the stock. Tidal Investments LLC boosted its stake in Merit Medical Systems by 1.0% in the 3rd quarter. Tidal Investments LLC now owns 10,398 shares of the medical instruments supplier’s stock worth $1,028,000 after purchasing an additional 104 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of Merit Medical Systems during the third quarter valued at approximately $207,000. TD Private Client Wealth LLC increased its position in shares of Merit Medical Systems by 13.9% during the third quarter. TD Private Client Wealth LLC now owns 1,732 shares of the medical instruments supplier’s stock valued at $171,000 after acquiring an additional 211 shares in the last quarter. Geode Capital Management LLC raised its holdings in Merit Medical Systems by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,357,265 shares of the medical instruments supplier’s stock worth $134,165,000 after acquiring an additional 17,490 shares during the last quarter. Finally, Barclays PLC lifted its position in Merit Medical Systems by 305.4% in the 3rd quarter. Barclays PLC now owns 112,727 shares of the medical instruments supplier’s stock valued at $11,142,000 after acquiring an additional 84,923 shares in the last quarter. Institutional investors own 99.66% of the company’s stock.

Insider Transactions at Merit Medical Systems

In other Merit Medical Systems news, CFO Raul Jr. Parra sold 29,646 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the completion of the sale, the chief financial officer now directly owns 16,361 shares in the company, valued at $1,603,705.22. This represents a 64.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director F. Ann Millner sold 12,500 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.55, for a total value of $1,269,375.00. Following the transaction, the director now owns 32,391 shares in the company, valued at approximately $3,289,306.05. The trade was a 27.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.70% of the company’s stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.